New Molecular Drug has Clinical Activity in Hepatocellular Carcinoma
Maria Reig MD PhD, Professor and Head of the Barcelona Clinic Liver Cancer (BCLC) Unit, Hospital Clinic Barcelona at Barcelona University, Spain.
BARCELONA, Spain—A phase one study of new drug targeting the monopolar spindle 1 enzyme was found to be safe—with reversible neutropenia as the commonest side effect—and to have clinical activity in patients with relapsed or refractory unresectable hepatocellular carcinoma (HCC). Maria Reig MD PhD announced the study findings at the 2022 European Organisation for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research (EORTC-NCI-AACR) Symposium on Molecular Targets and Cancer Therapeutics.
She gave the Audio Journal of Oncology’s Peter Goodwin more details of this new type of treatment, that she says works in a very different way from the current options for treating liver cancer.